APVO455 is a preclinical Nectin-4 x CD3 bispecific T-cell engager designed for tumors such as bladder, breast, NSCLC, and head and neck cancers, where Nectin-4 is highly expressed.

Paraffin blocks were collected from the Pathology Department’s archives. The pathologist reviewed H&E stained and immunostained slides to confirm the diagnosis and examine the immunohistochemical ...

AbCellera’s poster presentation is available for download here. About AbCellera’s T-Cell Engager Platform CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment.

AbCellera’s poster presentation is available for download here. About AbCellera’s T-Cell Engager Platform CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment.

CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding tumor targets and the CD3 protein on ...

About ABP-102/CT-P72 ABP-102/CT-P72 an investigational HER2 x CD3 bispecific T-cell engager designed using Abpro’s proprietary DiversImmune® platform to selectively target HER2-overexpressing tumor ...

The patient had the highest level of clonal gamma V delta 1 T cells (46.80%) and gamma V delta 2 T cells (1.21%) among CD3+ IL-17–producing cells.

Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317’s ability to activate CD40 in a ...

Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317’s ability to activate CD40 in a ...

Objective Improving patient selection and development of biological therapies such as vedolizumab in IBD requires a thorough understanding of the mechanism of action and target binding, thereby ...

Tumor tissue from 868 patients in the QUASAR trial (adjuvant fluorouracil/folinic acid v observation in stage II/III CRC) was analyzed by CD3 and CD8 immunohistochemistry. Pathologists, assisted by ...